Evidence map›Paper›PMID 23989431›Full record

ArticleLeukemia2014

Ph+ ALL patients in first complete remission have similar survival after reduced intensity and myeloablative allogeneic transplantation: impact of tyrosine kinase inhibitor and minimal residual disease.

V Bachanova, D I Marks, M-J Zhang, H Wang, M de Lima, M D Aljurf, M Arellano, A S Artz, U Bacher, J-Y Cahn and 25 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Leukemia, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 66 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
66citing papers in PubMed, 2 pooled it
6.2field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

66 citing papers in PubMed, 2 syntheses or guidelines pooled it, 134 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Article
  15. Transplant in ALL: who, when, and how?Hematology. American Society of Hematology. Education Program · 2024
    Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article

6 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

35 authors at 20 institutions in 8 countries.

V BachanovaBlood and Marrow Transplant Program, University of Minnesota Medical Center, Minneapolis, MN, USA.ORCID 000000029325432X
D I MarksBristol Adult BMT Unit, Bristol Children's Hospital, Bristol, UK.
M-J ZhangCenter for International Blood and Marrow Transplant Research (CIBMTR), Medical College of Wisconsin, Milwaukee, WI, USA.
H WangCenter for International Blood and Marrow Transplant Research (CIBMTR), Medical College of Wisconsin, Milwaukee, WI, USA.
M de LimaSeidman Cancer Center, University Hospitals Case Medical Center, Cleveland, OH, USA.
M D AljurfDepartment of Oncology, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia.
M ArellanoWinship Cancer Institute, Emory University, Atlanta, GA, USA.
A S ArtzDepartment of Hematology and Oncology, University of Chicago Medicine, Chicago, IL, USA.
U BacherKlinik und Poliklinik fur Stammzelltransplantation, Universitatsklinikum Hamburg-Eppendorf, Hamburg, Germany.
J-Y CahnDepartment of Hematology, University Hospital, Grenoble, France.
Y-B ChenDepartment of Bone Marrow Transplantation, Massachusetts General Hospital, Boston, MA, USA.
E A CopelanLevine Cancer Institute, Carolinas HealthCare System, Charlotte, NC, USA.
W R DrobyskiMedical College of Wisconsin, Milwaukee, WI, USA.
R P GaleImperial College, Section of Hematology, Division of Experimental Medicine, Department of Medicine, London, UK.
J P GreerDepartment of Hematology and Stem Cell Transplantation, Vanderbilt University Medical Center, Nashville, TN, USA.
V GuptaPrincess Margaret Hospital, Toronto, Ontario, Canada.
G A HaleDepartment of Pediatric Hematology and Oncology, All Children's Hospital, St Petersburg, FL, USA.
P KebriaeiDepartment of Stem Cell Transplantation and Cellular Therapy, MD Anderson Cancer Center, Houston, TX, USA.
H M LazarusSeidman Cancer Center, University Hospitals Case Medical Center, Cleveland, OH, USA.
I D LewisDepartment of Haematology and Bone Marrow Transplant Unit, Royal Adelaide Hospital/SA Pathology, Adelaide, South Australia, Australia.
V A LewisDepartment of Hematology and Oncology, Alberta Children's Hospital, Calgary, Alberta, Canada.
J L LiesveldDepartment of Hematology and Oncology, Strong Memorial Hospital, University of Rochester Medical Center, Rochester, NY, USA.
M R LitzowDepartment of Hematology and Internal Medicine, Mayo Clinic Rochester, Rochester, MN, USA.
A W LorenDepartment of Hematology and Oncology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
A M MillerDepartment of Oncology, Baylor University Medical Center, Dallas, TX, USA.
M NorkinDepartment of Hematology and Oncology, Shands HealthCare and University of Florida, Gainesville, FL, USA.
B OranDepartment of Stem Cell Transplantation and Cellular Therapy, MD Anderson Cancer Center, Houston, TX, USA.
J PidalaDepartment of Blood and Marrow Transplantation, Moffitt Cancer Center, Tampa, FL, USA.
J M RoweDepartment of Hematology, Rambam Medical Center, Haifa, Israel.
B N SavaniDepartment of Hematology and Stem Cell Transplantation, Vanderbilt University Medical Center, Nashville, TN, USA.
W SaberCenter for International Blood and Marrow Transplant Research (CIBMTR), Medical College of Wisconsin, Milwaukee, WI, USA.
R VijDepartment of Bone Marrow Transplantation and Leukemia, Barnes Jewish Hospital, Washington University School of Medicine, St Louis, MO, USA.
E K WallerBone Marrow and Stem Cell Transplant Center, Emory University Hospital, Atlanta, GA, USA.
P H WiernikOur Lady of Mercy Medical Center, Bronx, NY, USA.
D J WeisdorfBlood and Marrow Transplant Program, University of Minnesota Medical Center, Minneapolis, MN, USA.
Medical College of Wisconsin · USEmory University · USThe University of Texas MD Anderson Cancer Center · USUniversity Hospitals Cleveland Medical Center · USUniversity of Minnesota Medical Center · USVanderbilt University · USAlberta Children's Hospital · CAAlfaisal University · SABarnes-Jewish Hospital · USBaylor University Medical Center · USBristol Royal Hospital for Children · GBCalifornia University of Pennsylvania · USCarolinas Healthcare System · USHarvard University Press · USImperial College London · GBJohns Hopkins University · USMayo Clinic · USPrincess Margaret Cancer Centre · CARambam Health Care Campus · ILSouth Australia Pathology · AU

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
Data Resource for Analyzing Blood &Marrow TransplantsU24CA076518 · NCI · MEDICAL COLLEGE OF WISCONSIN · PI Amy M Moskop, Bronwen Shaw · 1998 to 2026
$105.2M
Easy-to-read Informed Consent for HCT Clinical TrialsU10HL069294 · NHLBI · MEDICAL COLLEGE OF WISCONSIN · PI HOROWITZ, MARY MARESCA · 2011 to 2016
$43.8M
University of Minnesota Clinical and Translational Science Institute (UMN CTSI)UL1TR000114 · NCATS · UNIVERSITY OF MINNESOTA · PI BLAZAR, BRUCE R · 2012 to 2015
$35.0M
RESEARCH TRAINING IN HEMATOLOGYT32HL007899 · NHLBI · UNIVERSITY OF WISCONSIN-MADISON · PI Jane Ellen Churpek · 1998 to 2026
$8.2M
University of Minnesota Clinical and Translational Science Institute (UMN CTSI)KL2TR000113 · NCATS · UNIVERSITY OF MINNESOTA · PI BLAZAR, BRUCE R · 2012 to 2015
$5.4M
NCATS NIH HHS KL2 TR000113NCATS NIH HHS UL1 TR000114NCI NIH HHS P30 CA016672NCI NIH HHS U24 CA076518NHLBI NIH HHS T32 HL007899NHLBI NIH HHS U10 HL069294
6 · The paper itself

Abstract

The efficacy of reduced intensity conditioning (RIC) allogeneic hematopoietic cell transplantation (HCT) for Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL) is uncertain. We analyzed 197 adults with Ph+ ALL in first complete remission; 67 patients receiving RIC were matched with 130 receiving myeloablative conditioning (MAC) for age, donor type and HCT year. Over 75% received pre-HCT tyrosine kinase inhibitors (TKIs), mostly imatinib; 39% (RIC) and 49% (MAC) were minimal residual disease (MRD)(neg) pre-HCT. At a median 4.5 years follow-up, 1-year transplant-related mortality (TRM) was lower in RIC (13%) than MAC (36%; P=0.001) while the 3-year relapse rate was 49% in RIC and 28% in MAC (P=0.058). Overall survival (OS) was similar (RIC 39% (95% confidence interval (CI) 27-52) vs 35% (95% CI 27-44); P=0.62). Patients MRD(pos) pre-HCT had higher risk of relapse with RIC vs MAC (hazard ratio (HR) 1.97; P=0.026). However, patients receiving pre-HCT TKI in combination with MRD negativity pre-RIC HCT had superior OS (55%) compared with a similar MRD population after MAC (33%; P=0.0042). In multivariate analysis, RIC lowered TRM (HR 0.6; P=0.057), but absence of pre-HCT TKI (HR 1.88; P=0.018), RIC (HR 1.891; P=0.054) and pre-HCT MRD(pos) (HR 1.6; P=0.070) increased relapse risk. RIC is a valid alternative strategy for Ph+ ALL patients ineligible for MAC and MRD(neg) status is preferred pre-HCT.

Indexed as

Bone Marrow TransplantationNeoplasm, ResidualPhiladelphia ChromosomeRemission InductionSurvival RateTransplantation ConditioningAdultAnimalsFemaleGuinea PigsHumansMaleMiddle AgedPrecursor Cell Lymphoblastic Leukemia-LymphomaProtein-Tyrosine KinasesTransplantation, HomologousProtein-Tyrosine Kinases

Identifiers

PMID23989431
PMCPMC3951192
OpenAlexW1981154777

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.